Source: Genomeweb

Saol Therapeutics: Saol Therapeutics, GeneDx Partner to ID Patients With Rare Mitochondrial Disease

The companies will work together to identify potential trial participants through genetic testing and a clinician awareness campaign.

Read full article »
Est. Annual Revenue
$25-100M
Est. Employees
100-250
David Penake's photo - CEO of Saol Therapeutics

CEO

David Penake

CEO Approval Rating

70/100

Read more